CD8A and head and neck squamous cell carcinoma: Immunostimulatory CAF subtypes can reduce CD8+ T cell exhaustion and enhance the T cell cytolytic profile, contributing to favorable clinical responses to anti-PD-1 therapy of HNSCC [34].